YTX-7739 is under clinical development by Kineta and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YTX-7739’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YTX-7739 overview

YTX-7739 is under development for the treatment of Parkinson's disease and glioblastoma multiforme (GBM). It is administered orally. The drug candidate is withaferin A analogue. The drug candidate is developed based on Company’s three integrated platforms which includes ultra high-throughput phenotypic screening (uHTS) platforms, human neuronal platform and drug-target identification platform. The therapeutic candidate acts by targeting stearoyl CoA desaturase. The drug candidate is also under development for the treatment of Lewy Body Dementia.

Kineta overview

Kineta formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of treatments for neurodegenerative diseases. The company uses its drug discovery platform for the development of its pipeline products. Kineta‘s pipeline product candidates include YTX-7739 for the treatment of Parkinson’s disease; YTX-9184 for the treatment of dementia with lewy bodies. Other pipeline also comprises of additional programs with undisclosed product candidates that are focused on frontotemporal lobar dementia (FTLD), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Kineta is headquartered in Boston, Massachusetts, the US.

For a complete picture of YTX-7739’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.